Biopharmaceutical stocks require time and patience. But when the company gets it right, investors get rewarded as they have with Kiniksa Pharmaceuticals (NASDAQ: KNSA). The stock is up over 100% in the last year. Much of that growth came after the company’s strong Q1 earnings report on April 28, in which it topped adjusted earnings per share (EPS) estimates by 9 cents, coming in at 27 cents.
At that time, the company announced the launch of a targeted direct-to-consumer TV campaign for ARCALYST in recurrent pericarditis. ARCALYST is the first and only U.S. Food & Drug Administration (FDA) approved therapy for recurrent pericarditis. It received this designation in 2021.
